首页> 外文期刊>EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology >Development of a novel adenosine-eluting guidewire (Adenowire) for coronary vasodilation during percutaneous coronary intervention
【24h】

Development of a novel adenosine-eluting guidewire (Adenowire) for coronary vasodilation during percutaneous coronary intervention

机译:在经皮冠状动脉介入期间开发一种新型腺苷洗脱导丝(腺喷裂),用于冠状动脉血管舒张

获取原文
获取原文并翻译 | 示例
           

摘要

Aims: Microvascular obstruction (MVO) and "no-reflow phenomenon" (NRP) remain barriers to optimal tissue perfusion after percutaneous coronary intervention (PCI). The purpose of this study was to develop, characterise, and test an adenosine-eluting guidewire (Adenowire) for coronary vasodilation. Methods and results: Utilising polyurethane chemistry, we developed a non-toxic pentameric form of adenosine (PA) that can be coated onto guidewires (Adenowire) and that allows continuous elution of adenosine into the distal vascular bed during PCI. We characterised PA with Fourier transform infrared spectroscopy, NMR and MALDI time-of-flight mass spectrometry, established its stability by calorimetry, and confirmed its safety by extensive toxicological testing. Adenowires reliably released adenosine in vitro over 60 minutes. In pigs, insertion of an Adenowire into the left circumflex or left anterior descending coronary artery resulted in immediate and sustained (40 minutes) vasodilation. Electron microscopy demonstrated smooth thin coating of the terminal portion of guidewires and showed lack of fibrin or platelet adhesion to the Adenowire after in vivo use. Conclusions: Since guidewires are the first devices to cross a culprit lesion, Adenowires would prophylactically medicate vascular beds with adenosine at the target site without the need for additional manipulations by the interventionalist.
机译:目的:微血管阻塞(MVO)和“无回流现象”(NRP)在经皮冠状动脉介入(PCI)后最佳组织灌注的障碍。本研究的目的是开发,表征和测试腺苷洗脱的导丝(腺红毛)以用于冠状动脉血管舒张。方法和结果:利用聚氨酯化学,我们开发了一种无毒的五聚体形式的腺苷(PA),其可以涂覆在导丝(腺系列)上并且允许在PCI期间连续地将腺苷连续洗脱到远端血管床中。我们用傅里叶变换红外光谱,NMR和MALDI飞行时间质谱仪进行了表征PA,通过热量测定建立了稳定性,并通过广泛的毒理学测试证实了其安全性。腺红迹可靠地在60分钟内在体外可靠地释放腺苷。在猪中,插入左旋环或左前期下降冠状动脉中的腺系导致立即和持续(40分钟)血管舒张。电子显微镜显示在体内使用后显示导丝的导丝末端部分的光滑薄涂层,并在体内使用后缺乏纤维蛋白或血小板粘附。结论:由于导丝是第一个交叉罪魁祸首病变的装置,因此腺道将用靶部位的腺苷预防血管床,而不需要通过介入主义者的额外操纵。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号